Skip to content

Xilis

13 viewers · 30d

Total raised

$19.4M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $19.4M
ROUNDS
1
INVESTORS
9
FOUNDED
N/A
HQ
Durham, NC
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
13

AI overview

Updated

Xilis, Inc. is a biotech company focused on transforming cancer treatment through innovative technologies that enable personalized medicine. By leveraging its proprietary MicroOrganoSphere™ technology, Xilis offers tailored therapeutic solutions that match cancer patients with the most effective treatments based on their individual tumor biology.

What sets it apart

Xilis stands out by creating microscale tumor models that closely mimic patient tumors, allowing for highly accurate predictions of treatment responses.

Funding history

1 round
Equity+1Apr 10, 2025
Form D
+$19.4M$19.4M total

Latest SEC filings

via EDGAR · CIK 0001796056
Form D · Apr 10, 2025View on EDGAR

Products

1 tracked

MicroOrganoSphere™ (MOS) Technology

Precision Oncology

The MicroOrganoSphere™ (MOS) technology allows the creation of miniature tumor models that preserve the critical biological characteristics of the original tumor. These microscale tumors enable clinicians to test various cancer therapies to determine which are most effective for individual patients.

  • Retains structure and genetic alterations of original tumors
  • Predicts drug response based on patient-specific biology
  • Facilitates high-throughput drug candidate screening

Links

WebsiteSEC EDGAR filings